The Egyptian Pharmacovigilance Center (EPVC) Newsletter, February 2026 edition, presents critical safety information for healthcare professionals, including a label update on drug‑induced aseptic meningitis, a local case report of excessive infant sleep following maternal escitalopram use during breastfeeding, and updates on EPVC educational and awareness initiatives.
This article provides a detailed medical analysis of these topics, exploring the pathophysiology, clinical presentation, and management of drug‑induced aseptic meningitis, as well as the risks of selective serotonin reuptake inhibitor (SSRI) exposure through breast milk. We also discuss the importance of pharmacovigilance in herbal medicine, the Vigitest 2026 live competition, and the “Together for Safe Medicine” initiative. Practical guidance for healthcare professionals on reporting adverse drug reactions (ADRs) and monitoring pregnancy exposures is provided. The article concludes with EPVC’s ongoing commitment to enhancing patient safety in Egypt.
1. Introduction
The Egyptian Pharmacovigilance Center (EPVC) continues its mission to monitor the safety of pharmaceutical products and disseminate essential safety information to healthcare professionals and the public. The February 2026 issue of the EPVC newsletter highlights several important pharmacovigilance topics:
- A label update from the Swiss regulatory authority (Swissmedic) regarding drug‑induced aseptic meningitis.
- A local case report of excessive sleep in an infant exposed to escitalopram through breast milk.
- EPVC participation in a scientific webinar on supplement and drug safety.
- The launch of Vigitest 2026 – a live pharmacovigilance competition.
- Recognition of top achievers in the “Together for Safe Medicine” initiative.
- Practical safety tips for pregnancy exposure monitoring and ADR reporting.
This article reviews these topics in depth, providing clinical context and evidence‑based recommendations for healthcare professionals.
2. Label Update: Drug‑Induced Aseptic Meningitis
2.1 Background and Key Message
The Swiss regulatory authority (Swissmedic) issued a label update emphasizing that medicinal products can be overlooked as triggers of aseptic meningitis. Aseptic meningitis is an inflammation of the meninges not caused by bacterial infection. While infectious causes (viruses, fungi) are well‑recognized, non‑infectious causes – including drugs – should always be considered in the differential diagnosis.
2.2 Drug Classes Associated with Aseptic Meningitis
According to the Swissmedic update, the following drug classes have been associated with aseptic meningitis:
| Drug Class | Examples |
|---|---|
| Non‑steroidal anti‑inflammatory drugs (NSAIDs) | Ibuprofen, mefenamic acid, diclofenac, naproxen |
| Antibiotics | Sulfonamides (e.g., cotrimoxazole), penicillins |
| Intravenous immunoglobulin (IVIg) | Various immunoglobulin products |
| Monoclonal antibodies | Infliximab, rituximab, others |
2.3 Pathophysiology
The exact mechanism of drug‑induced aseptic meningitis is not fully understood, but several hypotheses have been proposed:
- Immunological hypersensitivity reactions (Type III or Type IV): Immune complexes may deposit in the meninges, triggering inflammation.
- Direct chemical irritation of the meninges, particularly with cotrimoxazole and IVIg.
- For IVIg, an interaction between IgG antigens and meningeal vessels may cause cytokine secretion, leading to meningeal inflammation.
2.4 Clinical Presentation
| Feature | Details |
|---|---|
| Onset after first exposure | Hours to days |
| Onset after re‑exposure | Often minutes to a few hours |
| Symptoms | Headache, fever, neck stiffness, photophobia, nausea, vomiting |
| CSF findings | Lymphocytic pleocytosis, elevated protein, normal glucose |
| Prognosis | Usually self‑limited; symptoms resolve quickly after drug discontinuation |
2.5 Risk Factors
- Autoimmune diseases (e.g., systemic lupus erythematosus) predispose patients to aseptic meningitis after NSAID use.
- The side effect can also occur in otherwise healthy individuals.
2.6 Recommendations for Healthcare Professionals
| Recommendation | Action |
|---|---|
| Consider drug‑induced aetiology | In any patient presenting with meningitis symptoms, review the medication history, including over‑the‑counter drugs. |
| Suspect NSAIDs, antibiotics, IVIg, or monoclonal antibodies | Especially if symptom onset correlates temporally with drug administration. |
| Discontinue the suspected drug | Symptoms typically resolve rapidly after withdrawal. |
| Report suspected cases | Notify the national pharmacovigilance centre (EPVC) to contribute to safety data. |
In Egypt, this risk is already addressed in the product information for all affected active pharmaceutical ingredients.
3. Local Case Safety Report: Excessive Infant Sleep Following Maternal Escitalopram Use
3.1 Case Summary
The Regional Pharmacovigilance Center in Cairo received an Individual Case Safety Report (ICSR) concerning a parent‑child case:
- Mother: 33‑year‑old female with depression.
- Medication: Escitalopram 10 mg once daily at bedtime.
- Timing: Four days after starting escitalopram, the mother observed that her breastfed infant developed excessive sleepiness.
- Outcome: The mother continued treatment without interruption; the reaction had not resolved at the time of reporting.
3.2 Background: Escitalopram Pharmacology
Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used for major depressive disorder, generalized anxiety disorder, obsessive‑compulsive disorder, and other psychiatric conditions.
Mechanism of action: Escitalopram binds to the sodium‑dependent serotonin transporter (SERT) in the presynaptic neuron, blocking the reuptake of serotonin from the synaptic cleft. This increases synaptic serotonin levels, which helps regulate mood, perception, memory, appetite, sleep, and other behavioural processes.
3.3 Escitalopram and Lactation
Known facts from the Summary of Product Characteristics (SmPC):
- Escitalopram is excreted into human milk.
- Breastfeeding is not recommended during treatment.
- Published literature reports the presence of escitalopram and its metabolite desmethylescitalopram in human milk.
- Adverse effects in breastfed infants may include:
- Excessive sedation
- Restlessness and agitation
- Poor feeding
- Poor weight gain
There are no data on the effects of escitalopram on milk production.
3.4 Recommendations for Healthcare Professionals
| Recommendation | Details |
|---|---|
| Assess lactation status | Before prescribing escitalopram or other SSRIs to women of childbearing age, determine whether the patient is breastfeeding. |
| Avoid prescribing during breastfeeding | Unless the expected benefit clearly outweighs the potential risk to the infant (as per SmPC). |
| Counsel breastfeeding mothers | Inform patients that escitalopram passes into breast milk and may cause sedation, feeding difficulties, or poor weight gain in the infant. Advise them to report any behavioural or feeding changes immediately. |
| Use risk‑minimisation strategies if treatment is essential | Use the lowest effective dose. Avoid initiating treatment at bedtime if excessive infant sedation is a concern (maternal peak concentrations may coincide with prolonged infant exposure during sleep). |
| Monitor the breastfed infant | For signs of central nervous system depression (excessive sleepiness, difficulty waking, poor feeding). Monitor weight gain and developmental milestones. |
| Consider safer alternatives | Where clinically appropriate, consider non‑pharmacological treatments or medications with a more favourable safety profile during breastfeeding. Reassess treatment choice if the primary indication is insomnia rather than a psychiatric disorder. |
3.5 Clinical Implications
This case highlights the importance of parent‑child reporting – adverse reactions occurring in a breastfed infant should be reported as a linked case to the mother’s medication. Healthcare professionals must proactively counsel breastfeeding women about potential risks and monitor exposed infants closely.
4. EPVC News and Initiatives
4.1 Webinar on Supplement and Drug Safety in Egypt
EPVC participated in a scientific webinar titled “Ensuring Supplement and Drug Safety in Egypt,” hosted by the Egyptian Nutrition & Health Coaching Association (ENHCA). The focus was on pharmacovigilance in herbal medicine – a follow‑up to the recent EPVC newsletter on herbal ICSRs.
Key messages from EPVC:
- The vital role of pharmacovigilance in ensuring the safety of herbal products throughout their lifecycle.
- A comprehensive overview of national efforts to monitor adverse drug reactions (ADRs).
- Demonstration of how to report ADRs through the official Egyptian Drug Authority (EDA) website.
- Guidance on accessing the latest safety alerts and newsletters from the Pharmacovigilance General Administration (PVGA) to promote a culture of reporting.
4.2 Vigitest Competition 2026 – Live Pharmacovigilance Challenge
Following the successful launch of Vigitest in 2025 (monthly online quiz with monthly top contributors), the competition returns in 2026 as a live, interactive format.
What participants can expect:
- Rapid‑fire rounds
- Case simulations testing PV expertise in real time
How to join:
- Register via the Google Form: https://forms.gle/PbVtjcxpE3eQ67hL6 (or scan the QR code in the newsletter).
- Registered participants receive an invitation email one day before their competition round with the exact date, time, and platform instructions.
Registration closes soon – a unique opportunity to showcase PV skills and compete with peers.
4.3 “Together for Safe Medicine” – 7th Wave Top Achievers
EPVC successfully concluded the 7th wave of the initiative “Together for Safe Medicine” on 1 November 2025.
EPVC extends its appreciation to all participants for their dedication to promoting safe medicine practices and strengthening healthcare awareness across governorates.
4.4 EPVC Safety Tips: Pregnancy Exposure Monitoring
The newsletter provides practical pharmacovigilance points for managing drug exposure during pregnancy:
| Tip | Explanation |
|---|---|
| Document gestational age and trimester | Risk varies by timing of exposure; highest during the first trimester. |
| Capture complete drug details | Dose, duration, indication, start/stop dates, and concomitant medications (including OTC and herbal products). |
| Record pregnancy outcomes clearly | Live birth, miscarriage, congenital anomaly, preterm birth, or neonatal complications. |
| Assess seriousness | Congenital anomalies and fetal death are always considered serious. |
| Follow up ongoing pregnancies | Update cases after delivery to obtain final outcomes. |
| Be precise in documentation | Avoid vague descriptions; use confirmed medical diagnoses whenever possible. |
Key message: Timely and accurate reporting of pregnancy exposures strengthens drug safety monitoring and supports safer maternal and fetal health outcomes.
4.5 How to Report ADRs to EPVC
Healthcare professionals and the public can report adverse drug reactions to the Egyptian Drug Authority (EDA) through:
- Email: pv.followup@edaeqypt.gov.eg
- Hotline: 15301
- Website: EDA website
- Alternative: Report through a pharmacy, product distributor, or company hotline – they are required to forward reports to EDA.
Why your report matters: Every report contributes to the safety of medicines and patients worldwide.
5. Clinical Implications and Practical Guidance
5.1 Recognising Drug‑Induced Aseptic Meningitis
| Step | Action |
|---|---|
| Maintain high suspicion | In patients presenting with meningitis symptoms, especially if they are taking NSAIDs, antibiotics, IVIg, or monoclonal antibodies. |
| Review medication history | Include OTC drugs and recent changes. |
| Perform lumbar puncture | CSF analysis shows lymphocytic pleocytosis, normal glucose, and negative bacterial cultures. |
| Discontinue suspect drug | Symptoms typically resolve within days. |
| Report | Notify EPVC to help characterise this rare ADR. |
5.2 Managing SSRIs During Breastfeeding
| Scenario | Recommendation |
|---|---|
| Mother requires SSRI | Assess whether breastfeeding is essential; consider alternative medications with better safety profiles. |
| Escitalopram is prescribed | Use the lowest effective dose. Avoid bedtime dosing if infant sedation is a concern. |
| Infant shows excessive sleepiness, poor feeding, or poor weight gain | Evaluate for SSRI‑related adverse effects. Consider switching to another antidepressant or stopping breastfeeding (with appropriate formula feeding). |
| Mother continues breastfeeding | Monitor infant weight, feeding behaviour, and developmental milestones closely. |
5.3 Promoting a Culture of ADR Reporting
EPVC encourages all healthcare professionals to:
- Report all suspected ADRs, including those related to herbal products, supplements, and vaccines.
- Provide complete information (patient demographics, drug details, reaction description, outcome).
- Use the official EDA reporting channels (hotline 15301, email, website).
- Stay informed by subscribing to EPVC newsletters and safety alerts.
6. Conclusion
The February 2026 EPVC newsletter provides essential updates for healthcare professionals in Egypt and beyond. Key takeaways include:
- Drug‑induced aseptic meningitis – a rare but important ADR that can be caused by NSAIDs, antibiotics, IVIg, and monoclonal antibodies. Clinicians should suspect drug‑induced causes in patients presenting with meningitis symptoms, especially after new drug exposure.
- Escitalopram and breastfeeding – escitalopram passes into breast milk and can cause excessive sedation, poor feeding, and poor weight gain in infants. Prescribers should avoid escitalopram during lactation unless absolutely necessary, and monitor exposed infants closely.
- EPVC initiatives – The centre continues to promote pharmacovigilance through webinars, the Vigitest 2026 live competition, the “Together for Safe Medicine” awards, and practical safety tips for pregnancy exposure monitoring.
- Reporting matters – Every ADR report submitted to EPVC contributes to global drug safety knowledge. Healthcare professionals are encouraged to report suspected reactions promptly and completely.
By staying vigilant and actively participating in pharmacovigilance activities, healthcare professionals can help ensure safer use of medicines for all patients, including the most vulnerable – pregnant women, breastfeeding mothers, and their infants.
